New Lymphoma Treatment Promising
8-Year Survival Rate Was 86% With Bexxar in Previously Untreated Patients
WebMD News Archive
June 4, 2007 (Chicago) -- Nearly nine in 10 people with lymphoma given a
relatively new type of treatment that combines cancer-killing antibodies and
radiation are still alive eight years after being treated, researchers
The study also showed that half of people with previously untreated
follicular lymphoma have not suffered a relapse since undergoing a one-week
treatment with Bexxar.
Follicular lymphoma is a common form of non-Hodgkin's lymphoma and accounts
for about 15% of all cases. It’s a cancer of the lymph tissue, an important
part of the immune system.
Bexxar combines the antibody (tositumomab) with radioactive iodine and is
administered through an infusion. The antibody stimulates the body's immune
system to fight the cancer.
“The big advantage is that Bexxar is given in one week, with very little
toxicity,” says researcher Mark Kaminski, MD, professor of internal medicine at
the University of Michigan Comprehensive Cancer Center in Ann Arbor.
“In contrast, traditional chemotherapy regimens require several months of
therapy and is associated with a variety of toxicities,” he tells WebMD. Side
effects of conventional chemo include nausea, hair loss, and infections.
86% of Patients Still Alive at 8 Years
Bexxar was approved by the FDA in 2003 for the treatment of follicular
non-Hodgkin's lymphoma in patients who have not responded to initial therapy
with the drug Rituxan and who have relapsed following chemotherapy. But this is
the first study to use the drug in previously untreated patients.
The study included 76 people with advanced follicular lymphoma (stage III
and IV) who had not yet been treated for their disease. The patients were given
a one-week treatment with Bexxar and were followed for about eight years.
The research was presented here at the American Society of Clinical
Oncology’s annual meeting.
Results showed that 95% of the patients responded to the treatment; 75% had
a complete disappearance of the signs of their cancer.
At follow-up, the estimated eight-year overall survival rate was 86%. Fifty
percent of patients continued to show no signs of cancer. Of the 57 patients
who had a complete remission, two-thirds remained in remission.
Kaminski says the toxicity or hazardous side effects of Bexxar were
moderate, and none of the patients treated required transfusions or suffered
serious therapy-related complications.